Canada’s Legalization Timeline: Past to Present
August 9th, 2017
Policy, Top News
Canada’s path to legalization truly began April 23, 1923, when the House of Commons held a late night session to add cannabis to the country’s Confidential Restricted List under the Narcotics Drug Act Amendment Bill after vague mentions of a “new drug”. Adjusting to the change in law took time: the first seizure of cannabis by Canadian police wasn’t until 1937. Between 1946 – 1961, cannabis arrests only accounted for 2% of all arrests in Canada. As the US pushed reefer madness, Canada took a more measured approach to assessing cannabis’ risk.
On May 29th 1969, the Le Dain Commission was formed by the government, formally titled, “the Royal Commission of Inquiry in the Non-Medical Use of Drugs”. Their purpose was to assess the non-medical cannabis use in Canada. On January 26th,1972, the commission issued their report, encouraging the removal of criminal penalties concerning cannabis possession or use, though they would not endorse de facto legalization. Despite talking about the commission’s report, the two federal governments took no action to remove criminal penalties for cannabis.
For the first time in Canadian history, legal access to cured cannabis for medical reasons was allowed under a unique section 56 exemptions under the CDSA (Controlled Drugs and Substances Act) on June 9th, 1999. Not even a year later on July 31st, 2000, the R. v. Parker decision established that individuals with a medical need had the right to posses cannabis for medical reasons. This led to the institution of the MMAR.
The MMAR (Marijuana Medical Access Regulations) was enacted in July, 2001, slated to end on March, 31st, 2014. It was enacted to outlay the means and reasons that medical marijuana would be allowed. It consisted of three main parts: allowances to possess cured cannabis, license issuances to produce cannabis (including personal-use licenses as well as designated-person production licenses), and lastly, access to cannabis seeds or cured cannabis flower.
Before the MMAR’s termination date, on July 2013, the MMPR (Marijuana for Medical Purposes Regulations) was enacted to address the growing, sale and use of medical cannabis. Portions of the law went into effect progressively: first some changes on Oct. 1st, 2013, then more on March 31st, 2014, and the final elements of the change in legislation went into effect on March 31st, 2015.
The Supreme Court of Canada, in R. v. Smith set a precedent on June 11th, 2015, that limiting or infringing patient access to cannabis by only permitting dry cannabis is unconstitutional. Patients with need have the right to use and process cannabis products in Canada. A month later on July 8th, 2015, The Minister of Health issued exemptions on section 56 under the CDSA to allow producers with a license to process and sell cannabis oils as well as fresh buds and leaves, beyond just the dry cannabis product that the MMPR permitted.
Justice Minister Jody Wilson-Raybould announced that the ministers of Health and Public Safety were sorting out specifics concerning the legislation that would remove personal consumption of cannabis from the CDSA (Controlled Drugs and Substances Act), but, harsher penalties would be put into effect for dealers selling to children and individuals found to be driving under the influence of cannabis. This announcement came on November 26th, 2015.
Precedent was set by the decision in Allard v. Canada on February 24th, 2016: it found that mandating that patients get cannabis only from licensed producers infringed on the liberty and security rights of Canadian citizens established in section 7 of the Canadian Charter of Rights and Freedoms. This boiled out to the court determining that patients that needed cannabis for medical reasons didn’t have “reasonable access”.
On August 24, 2016, The ACMPR (Access to Cannabis for Medical Purposes Regulations) replaced the previous (MMPR) law. The law contains four parts: 1) Similar framework to the MMPR allowing for commercial growth of cannabis products in a quality-controlled environment. 2) Sets provisions for individuals to produce a set amount of cannabis for their own medical reasons, or, to select someone to grow it for them. 3+4) Transitional provisions that cover the continuation of MMPR practices by licensed producers, amendments to other regulations that referenced the MMPR, and lastly, provisions that enact the repeal of the MMPR and set the date of the ACMPR coming into force.
Final wording of the removal of cannabis consumption from the CDSA was reportedly “under discussion” as of March, 2017. The expected date that has been widely publicized as probable for when the new legislation will take effect is July 1st, 2018. This new legislation has been reported to give provinces the power to set the legal age for use, as well as regulate the methods of sales and distribution. When Canada legalizes cannabis, it will join only one other country in the world with federal level cannabis protections for consumption and growth: Uruguay.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.